Kusha Davar

Dr. Kusha Davar

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2022 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
KDKusha Davar
Kusha Davar
DCDevin Clark
Devin Clark
RCRobert M Centor
Robert M Centor
FDFernando Dominguez
Fernando Dominguez
BGBassam Ghanem
Bassam Ghanem
BSBrad Spellberg
Brad Spellberg
Like all fields of medicine, Infectious Diseases is rife with dogma that underpins much clinical practice. In this study, we discuss 2 specific examples of historical practice that have been overturned recently by numerous prospective studies: traditional durations of antimicrobial therapy and the necessity of intravenous (IV)-only therapy for specific infectious syndromes. These dogmas are based on uncontrolled case series from >50 years ago, amplified by the opinions of eminent experts. In contrast, more than 120 modern, randomized controlled trials have established that shorter durations of therapy are equally effective for many infections. Furthermore, 21 concordant randomized controlled trials have demonstrated that oral antibiotic therapy is at least as effective as IV-only therapy for osteomyelitis, bacteremia, and endocarditis. Nevertheless, practitioners in many clinical settings remain refractory to adopting these changes. It is time for Infectious Diseases to move beyond its history of eminent opinion-based medicine and truly into the era of evidenced-based medicine.

7 March 2023 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
SFSarah Freling
Sarah Freling
NWNoah Wald-Dickler
Noah Wald-Dickler
JBJosh Banerjee
Josh Banerjee
CCCatherine P Canamar
Catherine P Canamar
STSoodtida Tangpraphaphorn
Soodtida Tangpraphaphorn
BSBrad Spellberg
Brad Spellberg
We sought to compare the outcomes of patients treated with intravenous (IV)-only vs. oral transitional antimicrobial therapy for infective endocarditis (IE) after implementing a new Expected Practice within The Los Angeles County Department of Health Services (LAC DHS). We conducted a multi-centered, retrospective cohort study of adults with definite or possible IE treated with IV-only vs. oral therapy at the three acute care, public hospitals in the LAC DHS system between December 2018 to June 2022. The primary outcome was clinical success at 90 days, defined as being alive, and without recurrence of bacteremia or treatment-emergent infectious complications. We identified 257 patients with IE treated with IV-only (n=211) or oral transitional (n=46) therapy who met study inclusion criteria. Study arms were similar for many demographics; however, the IV cohort was older, and had more aortic valve involvement, hemodialysis patients, and central venous catheters present. In contrast, the oral cohort had a higher percentage of IE caused by methicillin-resistant S. aureus. There was no significant difference between the groups in clinical success at 90 days or last follow-up. There was no difference in recurrence of bacteremia or readmission rates. However, patients treated with oral therapy had significantly fewer adverse events. Multivariable regression adjustments did not find significant associations between any selected variables and clinical success across treatment groups. These results demonstrate similar outcomes of real-world use of oral vs. IV-only therapy for IE, in accord with prior randomized controlled trials and meta-analyses.

8 December 2021 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
KDKusha Davar
Kusha Davar
MWM R Wilson
M R Wilson
SMS Miller
S Miller
CCC Y Chiu
C Y Chiu
TVT Vijayan
T Vijayan
Psittacosis is a zoonotic infectious disease caused by the transmission of Chlamydia psittaci; it often presents as a pulmonary infection but rarely as disseminated disease. Because diagnoses of psittacosis are often underreported due to infrequent pathogen-specific testing, clinical metagenomic next-generation sequencing may be helpful to diagnose such an uncommon syndrome.

3 January 2024 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
PDF file
COChristian Olivo-Freites
Christian Olivo-Freites
KDKusha Davar
Kusha Davar
OGOscar Gallardo-Huizar
Oscar Gallardo-Huizar
TVTara Vijayan
Tara Vijayan
RYRamee Younes
Ramee Younes
: Flea-borne typhus is a vector-borne disease caused by Rickettsia typhi that occurs worldwide, except in Antarctica. In the United States, most cases are restricted to California, Hawaii, and Texas. The syndrome is characterized by nonspecific signs and symptoms: fever, headache, rash, arthralgia, cough, hepatosplenomegaly, diarrhea, and abdominal pain. Although flea-borne typhus can cause pulmonary, neurological, and renal complications, the cardiovascular system is rarely affected. We present a case of endocarditis resulting from flea-borne typhus diagnosed by blood microbial cell-free DNA testing that required valve replacement and antibiotic therapy for 6 months. In addition, we review 20 cases of presumed and confirmed cardiovascular manifestations resulting from flea-borne typhus in the literature.

24 June 2025 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
MPMatthew C Phillips
Matthew C Phillips
KDKusha Davar
Kusha Davar
SFSarah Freling
Sarah Freling
STSteven Y C Tong
Steven Y C Tong
TLTodd C Lee
Todd C Lee
BSBrad Spellberg
Brad Spellberg
Clinicians are constantly bombarded with an onslaught of newly published data, yet they must make clinical decisions despite a dearth of clinical data. Sometimes, they may fall back on clinical practices entrenched by experience, unaware that they are upheld by dogmatic tradition rather than robust evidence. Ideally, the totality of evidence must be assessed and utilized for clinical decision-making, irrespective of entrenched orthodoxy. Here, we explore the questions, how much evidence is needed to revise established clinical practices and, more fundamentally, can data alone truly catalyze such shifts.

1 August 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
DCDevin C Clark
Devin C Clark
RBRachel Baden
Rachel Baden
JBJosh Banerjee
Josh Banerjee
RBRita Bedrossian
Rita Bedrossian
HCHannah Chute
Hannah Chute
SFSarah R Freling
Sarah R Freling
Background: Oral cefadroxil has favorable pharmacokinetics for the treatment of bloodstream infection (BSI) and osteomyelitis caused by Gram-positive cocci (GPC), but limited clinical data exist. Methods: We conducted a multicenter, retrospective cohort study between September 2022 and April 2025 assessing cefadroxil versus intravenous (IV)-only or other oral transitional therapy in adults with susceptible GPC BSI, with or without osteomyelitis. No patients with endocarditis, vertebral osteomyelitis, or prosthetic or central nervous system infections were included. Primary outcome was treatment success, defined as 90-day survival without infection progression or relapse. Prioritized secondary outcomes included all-cause mortality, recurrent bacteremia, and readmission at 90 days. Results: Of 323 patients with BSI, 58 were treated with cefadroxil, 72 IV only, and 193 with other oral antibiotics. Rates of osteomyelitis were comparable in each cohort, but skin and soft-tissue infections were a more common source of bacteremia in cefadroxil (52%) than either IV (28%, P = .01) or orally (PO) (31%, P = .003) cohorts. Staphylococcus aureus was more frequent in the IV (60%) than cefadroxil cohort (36%, P = .008). Nevertheless, cefadroxil-treated patients had a similar case mix index, expected mortality, and expected length of stay as the IV and PO cohorts, indicating comparable populations. Treatment success was similar for cefadroxil (91%), IV (94%, P = .51), and other oral (93%, P = .63) cohorts. Mortality, hospital readmission, and adverse events were comparable between groups. Conclusions: We found similar outcomes for cefadroxil and IV or PO alternatives in patients with GPC BSI, absent endocarditis, vertebral osteomyelitis, prosthetic or central nervous system infection. Cefadroxil was well-tolerated without observed severe adverse events. Main Point: In this multicenter, retrospective cohort study, cefadroxil was an effective and safe oral transitional therapy for bloodstream infections, with or without nonvertebral osteomyelitis.